Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Highlights| Protein Name | Frizzled class receptor 10 |
| Gene Name | FZD10 |
| Uniprot | Q9ULW2 (Human); Q8BKG4 (Mouse) |
| Synonym | Fz10; FzE7; CD350; FZ-10; hFz10; frizzled-10; frizzled 10, seven transmembrane spanning receptor; frizzled family receptor 10; frizzled homolog 10 |
| Background | FZD10, also known as frizzled class receptor 10, frizzled family receptor 10, frizzled (Drosophila) homolog 10, Fz-10, hFz10, FzE7, CD350 antigen or CD350, is a 65k Da cell surface receptor that belongs to the frizzled gene family and in humans, encoded by the chromosome 12q24.33. This protein consists of 581 amino acids with a 7-transmembrane domain, an N-terminal cysteine-rich domain (CRD) and a C-terminal Ser/Thr-Xxx-Val motif. A great deal of FZD10 mRNA, about 4.0 kb in size, is detected in the placenta and fetal kidney, followed by fetal brain and lung. When it comes to adults, the mRNA level of this gene is abundant in the cerebellum. There is report indicated that FZD10 is highly expressed in cervical cancer cell lines of HeLa S3, and moderately in colon cancer cells, SW480. |
Creative Biolabs offers comprehensive range of membrane protein products empowers your unique research needs.
| CAT# | Product Name | Expression System | Protein Length | Solubilizing Agents |
| S01YF-1023-KX446 | NativeExtract™ Human FZD10 Membrane Protein (Full length, Super Nanodisc) | HEK293 cell | Full length | Native Nanodisc |
| MPX3635K | MemDX™ Membrane Protein Human FZD10 Expressed in vitro E.coli expression system, Full Length of Mature Protein | E.coli cell-free | Full length | Detergent |
| MP0384X | MemDX™ Membrane Protein Human FZD10 (Frizzled class receptor 10) for Antibody Discovery | Wheat germ cel-freel | Full length | Liposome |
| S01YF-0423-KX335 | MemDX™ Membrane Protein Human FZD10 (21-161aa) Expressed in HEK293, C-Human Fc tag | HEK293 cell | Partial | N/A |
| MPX0031K | MemDX™ Membrane Protein Human FZD10 Expressed in Mammalian Cell for Antibody Discovery, Partial (21-161aa) | Mammalian cell | Partial | N/A |
| Please for more products or customization | ||||
R***n: Custom expression systems delivered FZD10 within 4 weeks.
02/Jul/2023
K***an: Unmatched technical support enabled immediate integration into Wnt signaling models.
23/Mar/2024
FZD10 Gene Therapy Development
We provide tailored solutions to meet your specific requirements. Please for more services.
siRNA-Mediated FZD10 Silencing for Synovial Sarcoma Intervention
Creative Biolabs offers siRNA-mediated FZD1 silencing services for synovial sarcoma intervention. RNA interference (RNAi) using small interfering RNAs (siRNAs) represents a precision strategy to silence FZD10 overexpression in synovial sarcoma. Therapeutic siRNAs targeting FZD10 mRNA induce degradation via the RNA-induced silencing complex (RISC), effectively reducing oncogenic Wnt/β-catenin signaling. For instance, in vivo studies demonstrate that systemic delivery of FZD10-specific siRNA nanoparticles suppresses tumor growth by >60% in preclinical synovial sarcoma models. Creative Biolabs' proprietary lipid-based encapsulation technology enhances siRNA stability and tissue-specific biodistribution, ensuring robust target engagement with minimal off-tumor effects. This approach is further bolstered by screening platforms to identify compounds disrupting FZD10-importin-β interactions, a critical axis for nuclear localization and oncogenesis.
FZD10 Knockout for Wnt Pathway Modulation
Creative Biolabs offers FZD10 knockout services for Wnt pathway modulation. Gene editing enables permanent inactivation of FZD10 alleles, offering a durable solution for Wnt-hyperactive cancers. By designing single-guide RNAs complementary to FZD10's ligand-binding domain, researchers achieve >90% knockout efficiency in colorectal carcinoma cell lines, leading to apoptosis and reduced metastatic potential. Creative Biolabs' optimized delivery systems, including AAV vectors with tissue-specific promoters, minimize off-target edits while maximizing therapeutic specificity. Combinatorial approaches—pairing FZD10 ablation with LRP5/6 inhibitors—synergistically suppress aberrant Wnt signaling, highlighting a versatile strategy for personalized oncology.
Creative Biolabs offers comprehensive and innovative services to drive the development of FZD10 cell therapy. Please for more services.
FZD10-Specific CAR-T Cell Engineering for Solid Tumors
Creative Biolabs offers FZD10-specific CAR-T cell engineering services. Chimeric antigen receptor (CAR)-T cells engineered to recognize FZD10-positive tumors exploit the receptor's overexpression in synovial sarcoma and gastric cancers. Preclinical models show that FZD10-directed CAR-T cells eliminate tumor cells with >80% specificity, validated via flow cytometry and in vivo imaging. Creative Biolabs' lentiviral transduction protocols ensure stable CAR expression, while safety switches mitigate cytokine release syndrome risks. This modality is complemented by biomarker panels quantifying FZD10/LRP5 co-expression to stratify responsive patient cohorts.
Ex Vivo FZD10-Knockout Hematopoietic Stem Cell Transplantation
Creative Biolabs offers ex vivo FZD10-knockout hematopoietic stem cell development services. Disrupting FZD10 in hematopoietic stem cells (HSCs) via base editing prevents Wnt-driven clonal dominance in myelodysplastic syndromes. Edited HSCs engraft successfully in murine models, restoring balanced differentiation without leukemic transformation. Creative Biolabs' electroporation systems achieve >70% editing efficiency, ensuring clinical scalability. Ongoing trials integrate this approach with pharmacologic Wnt inhibitors to address resistance mechanisms.
Creative Biolabs' expertise in siRNA design, optimization, and cell therapy development ensures robust preclinical-to-clinical translation. Our advanced platforms—from in vivo biodistribution profiling to CAR-T functional validation—provide end-to-end solutions for targeting FZD10 in oncology. to tailor a development strategy leveraging our cutting-edge technologies and disease models.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
